HIGHLIGHTS
SUMMARY
Biochemical studies (measurement of IC50 and Ki ) confirmed the in_vitro inhibition of class A and class C by relebactam and vaborbactam. In this study, the in_vitro activities of ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam and comparators were tested against a collection of CR non-CPE received at the French National Reference Center (F-NRC). Of note, contrary to meropenem/vaborbactam combination in which the meropenem dosage corresponds to the high dosage of meropenem (2 g), the dosage of imipenem included in the imipenem/relebactam combination corresponds to the standard dosage of imipenem (0 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.